Author: itembalabantu
-
Finerenone’s commercial moat (Part 3): “the only nonsteroidal MRA with hard-outcome trials” — a real but time-limited advantage boxed in on three sides
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment or medical advice. The 30-second version What. Finerenone (Bayer’s Kerendia) is currently the only nonsteroidal MRA (nsMRA) with hard-outcome RCT evidence. That single fact is its commercial moat: every competitor is on a surrogate…
-
The three-pillar combination in CKM — where the finerenone + SGLT2i + GLP-1 case is proven, and where it is still an assumption
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The “three-pillar” combination in cardio-kidney-metabolic (CKM) disease stacks three non-overlapping mechanisms — SGLT2 inhibitor (hemodynamic), GLP-1 receptor agonist (metabolic) and finerenone (anti-inflammatory / anti-fibrotic). CONFIDENCE (NEJM…
-
Does finerenone move hard outcomes, or mainly organ and morbidity endpoints? A close read of FIDELITY, FINEARTS-HF and FINE-HEART
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Finerenone (a non-steroidal mineralocorticoid receptor antagonist) reduced kidney and heart-failure morbidity endpoints consistently across three pooled trial layers. But the single hardest endpoint, cardiovascular death,…
-
The finerenone landscape — a nonsteroidal MRA as the third pillar of CKM care, and what is still an open question
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that targets inflammation and fibrosis rather than blood pressure and volume — a mechanism that does not overlap…
-
The clinical cost behind the GLP-1 headline — reading lean-mass loss, discontinuation, rebound, and safety signals by evidence tier
This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → The clinical cost behind the GLP-1 headline — lean-mass loss, discontinuation, weight rebound and safety signals, separated by evidence tier. The full text now lives in the…
-
The GLP-1 commercial map (Part 3): not “who wins” but “who gets access” — the Novo–Lilly duopoly and the access bottleneck
This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → The GLP-1 commercial map, where the binding constraint is access and reimbursement rather than which manufacturer wins on efficacy. The full text now lives in the updated…
-
The next-generation obesity pipeline: from “how much you lose” to “at what cost”
This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → The next-generation obesity pipeline, and why the competitive question is shifting from how much weight a drug removes to what that removal costs in lean mass, tolerability…
-
Do incretins move hard outcomes in CKM, not just weight? A close read of SELECT, FLOW and SUMMIT
This article has been superseded. An expanded and updated version was published on 25 July 2026 and is now the version of record. Read the current version → Whether GLP-1 receptor agonists improve hard cardiovascular and kidney outcomes in cardio-renal-metabolic disease, rather than weight alone — read against the SELECT, FLOW and SUMMIT trials. The…
-
The GLP-1 / incretin landscape — why the question moved from “how much weight?” to “what does it change?”
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The incretin (GLP-1) class is expanding beyond glucose and weight into cardiovascular, kidney and heart-failure indications. In the only two head-to-head trials, the dual agent (tirzepatide)…
-
Computing’s Single Point of Failure: Why the Semiconductor Supply Chain Is Tied to a Few Places on the Map
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. The ultimate bottleneck for AI and computing is neither chip performance (physics) nor capital (economics), but a geopolitical structure in which advanced logic, EUV lithography, HBM, and upstream materials…
